$ALT

Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Digimarc Corporation (NASDAQ: DMRC); Nutex Health Inc. (NASDAQ: NUTX); and Quantum Corporation (NASDAQ: QMCO): Grabar Law Office is Investigating Claims on Your Behalf - Altimmune (NASDAQ:ALT), Digimarc (NASDAQ:DMRC)

PHILADELPHIA, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Grabar Law Office is investigating claims on behalf of shareholders of Altimmune, Inc. ALT. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Original reporting
Benzinga · Globe Newswire
Published Sep 8, 2025, 2:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 9, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Digimarc Corporation (NASDAQ: DMRC); Nutex Health Inc. (NASDAQ: NUTX); and Quantum Corporation (NASDAQ: QMCO): Grabar Law Office is Investigating Claims on Your Behalf - Altimmune (NASDAQ:ALT), Digimarc (NASDAQ:DMRC) — source image
Decision brief

The 30-second read

$ALTBearishLow
01

Why it matters

Legal issues may cause short-term volatility in Altimmune's stock; other stocks are unaffected.

02

Market read

The news primarily impacts Altimmune with potential sector-wide implications in biotech, but overall market impact remains limited.

03

What to watch

Market overreaction may present short-term buying opportunities; broader industry trends should be considered.

Timing: Long-term

Background

The investigation pertains to potential breaches of fiduciary duties by Altimmune's management, raising concerns among shareholders.

Company-level read

Ticker impact

$ALTBearishMedium confidence
Context

High relevance due to ongoing legal investigation and shareholder claims.

Expected impact

Potential short-term decline of 5-10%, depending on investigation outcomes.

Evidence & confidence

Legal investigations often lead to increased volatility and investor concern, but the impact depends on the investigation's findings and market perception.

$DMRCNeutralHigh confidence
Context

Moderate relevance; sentiment is neutral, and no direct legal issues are reported.

Expected impact

Minimal impact; expect sideways trading.

Evidence & confidence

Neutral sentiment and lack of direct connection to the investigation imply limited influence on stock price.

$QMCONeutralHigh confidence
Context

Low relevance; sentiment is neutral, and the company is not mentioned in the investigation.

Expected impact

No significant change expected.

Evidence & confidence

Absence of any association with the investigation indicates minimal impact.

$NUTXNeutralHigh confidence
Context

Low relevance; neutral sentiment and no direct link to the investigation.

Expected impact

Likely stable with minor fluctuations.

Evidence & confidence

No direct or indirect connection reduces the likelihood of significant price movement.

Market effects

Potential negative sentiment in biotech and life sciences sectors due to legal investigations.

Limited; primarily affects US-listed companies.

Minimal; news is company-specific with limited global implications.

Counterpoint

Legal investigations can sometimes lead to positive outcomes if allegations are unfounded, potentially resulting in a rebound.

Key entities

  • Grabar Law Office

    Law firm investigating shareholder claims.

  • Altimmune, Inc.

    Company under investigation for fiduciary breaches.

Related articles

$NUTXMed

NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Nutex Health Inc. (NASDAQ: NUTX) reported Q2 2026 results for the three and six months ended June 30, 2026. Net income attributable rose to $65.8M (diluted EPS $9.38) for Q2, versus a loss in 2025. Six-month net income was $112.6M (EPS $15.87). Revenue fell to $427.2M for six months. Operating cash flow was $109.7M. Hospital visits increased.

$NUTXMed

Nutex Health Inc. (NUTX): Results of Operations and Financial Condition

Nutex Health Inc. (NUTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nutx-20260630xexx99.htm EX-99.1 Document NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS HOUSTON, TX − (PRNewswire) – AUGUST 6, 2026 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and six

$ALTMedAI 8/10

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial

Altimmune (NASDAQ:ALT) reported Phase II results for pemvidutide in alcohol use disorder. The WHO risk-drinking-level endpoint improved in 64.4% vs 34.8% on placebo (p=0.0049), and zero heavy drinking days increased with p=0.0066. PEth fell by 175.3 ng/mL vs unchanged on placebo (p=0.0001). Safety was generally tolerable; Phase III AUD discussions with regulators are next.

$ALTMedAI 8/10

Why is Altimmune stock surging today? By Investing.com

Altimmune said its RECLAIM Phase 2 trial of pemvidutide for moderate to severe alcohol use disorder met the primary endpoint, with 2.4 mg producing a statistically significant reduction in heavy drinking days per week versus placebo over 24 weeks (treatment effect 1.45 days). It also met secondary endpoints, and the company plans an End-of-Phase 2 meeting with the FDA. Shares rose 11.5% pre-open.

$ALTMedAI 8/10

Altimmune stock surges 18% on positive trial results By Investing.com

Altimmune Inc. (NASDAQ:ALT) shares rose 18% after it reported positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The study met its primary endpoint with a statistically significant reduction in heavy drinking days versus placebo (4.20 vs 2.75 per week at week 24, p=0.0014). Secondary endpoints and safety data were also favorable, and the company plans an FDA End-of-Phase 2 meeting.

$QMCOMed

Two up quarters in a row for Quantum

Quantum reported fourth fiscal quarter 2026 results for the period ended March 31, 2026. Revenue rose to $78 million, up 27.3% year-on-year and above $68 million guidance; GAAP net loss was $9.5 million. Full-year revenue was $279.6 million and GAAP net loss $101 million. CEO Hugues Meyrath cited strong AI-driven demand but said backlog conversion was constrained by disk/tape supply and IBM tape-drive delivery. Next-quarter revenue guidance: $75 million ± $2 million.